ClinicalTrials.gg

Program

BAT5906

A development code. Also written as “BAT5906 injection”, “2.5mg of BAT5906” and “4.0mg of BAT5906”.

Its studies are mostly in Macular Degeneration · Macular Edema, led by Bio-Thera Solutions.

Furthest: phase 3, since Jun 13, 20225 company-led studies, 1 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bio-Thera Solutions51 open or runningphase 3since Jun 13, 2022Nov 4, 2019Apr 30, 2027phase 3 · NCT07515079

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2019First study: phase 1 study in Macular DegenerationFirst studyNCT04151212 · 24 enrolled · China
  2. Jun 22, 20202 phase 2 studiesNCT05141994, NCT04772105
  3. Jun 13, 2022Phase 3 study in Macular DegenerationNCT05439629 · 488 enrolled · China
  4. Mar 23, 2026Phase 3 study in Diabetic Macular Edema (DME)NCT07515079 · 406 planned · China

Ahead

  1. Apr 30, 2027Primary completion: phase 3 study in Diabetic Macular Edema (DME)NCT07515079

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07515079Diabetic Macular Edema (DME) · China3RecruitingApr 30, 2027406
NCT05439629Macular Degeneration · China3CompletedApr 22, 2025488
NCT05141994Wet Age-related Macular Degeneration · China2CompletedSep 6, 202248
NCT04772105Diabetic Macular Edema · China2CompletedNov 6, 202360
NCT04151212Macular Degeneration · China1CompletedFeb 28, 202124

How it is read

Names in the registry

  • “BAT5906 injection”, 3 entries
  • “2.5mg of BAT5906”, 2 entries
  • “4.0mg of BAT5906”, 1 entry
  • “4mg of BAT5906”, 1 entry

Codes read as this program: BAT5906.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
BAT5906 (Bio-Thera Solutions): development program | ClinicalTrials.gg